Results 231 to 240 of about 2,778,104 (252)

Novel Lipoprotein (a) Therapies: A Comprehensive Review. [PDF]

Curr Atheroscler Rep
Ebubechukwu U, Ugoala O, Shahid R, Kulkarni A.   +3 more
europepmc   +1 more source

Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes

Current Pharmaceutical Design, 2020
Background: Concerns of elevated cardiovascular risk with some anti-diabetic medications warrant-ed trials on the cardiovascular outcome to demonstrate cardiovascular safety of newly marketed anti-diabetic drugs.
Panagiota Stampouloglou, Dimitris Tousoulis, Gerasimos Siasos   +2 more
exaly   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Biomaterials as Haemostatic Agents in Cardiovascular Surgery: Review of Current Situation and Future Trends

Polymers, 2022
Horatiu Moldovan, Iulian Vasile Antoniac, Elisabeta Bádila   +2 more
exaly  

Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms

Cardiovascular Research, 2022
Javed Butler, Gianluigi Savarese
exaly  

Cardiovascular drugs and lipid regulating agents in surface waters at global scale: Occurrence, ecotoxicity and risk assessment

Science of the Total Environment, 2020
Yanbin Zhao, Kun Zhang, Karl Fent
exaly  

Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta-analysis of randomized controlled trials with external adjudication of events

Diabetes, Obesity and Metabolism, 2023
Marco Gallo, Matteo Monami, Edoardo Mannucci   +2 more
exaly  

Cardiovascular and Cardioprotective Agents in 2021

Current Pharmaceutical Design, 2021
Manfredi Rizzo
exaly  

Preventing Cancer, Cardiovascular Disease, and Diabetes: A Common Agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association*†§

Ca-A Cancer Journal for Clinicians, 2004
Yuling Hong, Robert A Smith, Colleen Doyle   +2 more
exaly